Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
February 27, 2024
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, will kick things off with a look at the quarter and what's happened recently. Fady Malik, EVP of R&D, will share updates on aficamten, with a focus on SEQUOIA-HCM and FOREST-HCM. Stuart Kupfer, SVP and Chief Medical Officer, will give further aficamten updates tied to ACACIA-HCM and MAPLE-HCM, and he'll also cover CK-586 and CK-136. Andrew Callos, EVP and Chief Commercial Officer, will talk about commercial readiness efforts for aficamten. Robert Wong, VP and Chief Accounting Officer, will walk us through the financial picture for the quarter just ended. Then, to wrap up, Robert Blum will go over our 2024 financial guidance and corporate development strategies, and before we finish he'll review the key milestones we expect this year. Please be aware that some parts of what we discuss next, including answers we give to questions, include statements about future events and performance instead of historical facts, and those are forward-looking statements. What actually happens could differ materially from what those forward-looking statements project. Details about factors that might make our actual results differ materially from what those forward-looking statements describe can be found in our SEC filings, including the current report on our fourth quarter 2023 financial results furnished to the SEC today on Form 8-K. We have no obligation to update any forward-looking statements after this call. And with that, I'll hand the call over to Robert.
Robert Blum
executiveThanks, Diane, and I'm glad all of you could join us today. For our company, Q4 of 2023 represented a transformational turning point, since we turned the corner on SEQUOIA-HCM, our Phase III clinical study of aficamten, which is being developed as a possible therapy for patients suffering from hypertrophic cardiomyopathy, or HCM. The data exceeded expectations that were already elevated, and 2024 began with us operating at full power, renewing our dedication to getting ready for regulatory talks and filings with a sense of urgency. Behind SEQUOIA-HCM, we're carrying out a wide-ranging clinical development program, and we're also ramping up the next stage of our commercial readiness efforts. During this call, Fady is going to go over our strategy for presenting and publishing the primary findings along with other results from SEQUOIA-HCM, which will provide more detail regarding how effective and safe our cardiac myosin inhibitor—the next in its class—is; plus, he'll address the fact that we are now proceeding rapidly with regulatory filings around the world. After that, Andrew will speak about the careful steps we're taking to establish a distinct commercial position for this next-in-class opportunity. While SEQUOIA-HCM matters greatly for getting us to commercialization, our pipeline holds considerably more that we think will substantially release shareholder value as the company keeps maturing. Stuart is going to walk us through where things stand with MAPLE-HCM and ACACIA-HCM — those are the two extra Phase III studies of aficamten. What those trials offer is a possible pathway toward widening how cardiac myosin inhibitors get used, potentially letting them become a first-line option for obstructive HCM, and they could also deliver a fresh choice for the rising population of nonobstructive HCM patients. You're going to hear that excitement and activity around these studies have picked up following the good news from SEQUOIA-HCM. That said, plenty of work still lies between us and getting aficamten into patients' hands, though I have every confidence we can pull off our bold plans. You're going to get the full picture shortly, but the headline is that we closed out 2023 with a really solid balance sheet, and that's because we kept a tighter lid on spending throughout the year. On top of that, during Q4 and into the early part of this year, we boosted the cash we're holding through a capital injection that came from our at-the-market, or ATM, equity facility. Today we're glad to share our financial guidance, which shows roughly two years of runway when you factor in the money we have on hand plus the money we can access — and that's even with the higher operating expenses we're expecting for 2024. One more thing: we recently let everyone know that Ching Jaw is stepping away from the CFO role so he can focus on his personal health. Ching's exit has nothing to do with how our business is doing, and he and the company parted ways on good terms. Our senior leadership team stands behind the choice he made for his own well-being, and we want to say thank you for everything he has given to this company. Ching assembled a solid team that a lot of you probably recognize, such as Robert Wong, who serves as VP and Chief Accounting Officer, and Matt Yang, who is VP of Corporate Finance and FP&A. Together with the teams those two have built, we're confident that Ching leaving will barely affect the day-to-day finance operations. Our business development group remains under the leadership of Libby Schnieders, our SVP of Business Development, whose tenure with the company spans over 20 years, so no changes are anticipated in that area. In addition, because we recognized that Ching would have to prioritize his health, we brought on an experienced consultant during Q4 of 2023; this individual had previously served as CFO at a publicly traded biopharma firm and offers substantial know-how in financial planning and structured finance transactions. Throughout this transition, he will continue working side by side with me, as a nationwide search for Ching's successor has already been launched, and we expect that individual to possess international commercial and capital allocation experience appropriate for operations that are maturing. Cytokinetics sees a bright road ahead in 2024 and beyond. We're getting closer to potentially bringing to market the very first treatment born from our trailblazing, industry-leading work in muscle biology — and more will come as we continue pushing our R&D efforts forward. Being where we are today feels like good fortune, yet it wasn't luck that got us here. It resulted from meticulous preparation, risk mitigation, forward-looking strategy, persistence, and commitment. What we're building is a specialty cardiology business with aficamten at its core, and we have the pipeline, the enthusiasm, and the team required to make that vision real — something we expect will generate even greater returns for shareholders. With that, I'll hand the call to Fady, please.
Fady Malik
executiveThank you, Robert. Over the course of this quarter, we presented topline findings from SEQUOIA-HCM, and those findings, as Robert noted, came in above what we had anticipated. This represented a genuinely remarkable achievement, one that speaks to tremendous dedication from a great many people — our investigators, the study staff, the patients, and naturally, everyone on our teams at Cytokinetics. According to the SEQUOIA-HCM data, aficamten treatment produced a substantial gain in exercise capacity relative to placebo, raising peak oxygen uptake — peak VO2 — as assessed through cardiopulmonary exercise testing, with a least squares mean difference of 1.74 milliliters per kilogram per minute and a p-value of 0.000002. Aficamten's treatment effect held consistently across every prespecified subgroup, mirroring baseline patient characteristics and treatment approaches, among them individuals both on and off background beta blocker therapy. Across all 10 prespecified secondary endpoints, we saw statistically significant and clinically meaningful gains, with a p-value below 0.0001. These included the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at weeks 12 and 24, the share of patients achieving at least a 1 class improvement in New York Heart Association functional class at weeks 12 and 24, the shift in provoked left ventricular outflow tract gradient along with the percentage of patients whose gradient dropped under 30 millimeters of mercury at weeks 12 and 24, plus exercise workload and guideline eligibility for septal reduction therapy. Such favorable outcomes mirror swift and durable gains in symptoms, functional capacity, and heart failure status. Aficamten's tolerability was good, with an adverse event profile matching that of placebo. Treatment emergent serious adverse events arose in 8 patients, or 5.6%, taking aficamten, versus 13 patients, or 9.3%, on placebo. Core echocardiographic left ventricular ejection fraction, or LVEF, came in under 50% for 5 patients, or 3.5%, on aficamten, against 1 patient, or 0.7%, on placebo. Crucially, no cases emerged of worsening heart failure or treatment interruptions tied to low LVEF. Although this topline data offers a fairly thorough view of the therapy's overall impact, we have a broad plan in place to disclose the primary findings and further analyses with greater depth through a series of manuscripts and presentations. We anticipate the earliest of these will take place at Heart Failure 2024, the Annual Meeting of the Heart Failure Association of the European Society of Cardiology, happening in May in Lisbon. Beyond the primary SEQUOIA-HCM results, we intend over the months ahead to present and publish important data that could help support aficamten's differentiated profile. One key analysis involves evaluating aficamten's clinical effectiveness in patients across multiple endpoints in aggregate, looking at how broadly patients in SEQUOIA-HCM improved. In a separate one, we plan to detail the dosing and safety experience from SEQUOIA-HCM, which we think sheds light on the potential safety and monitoring requirements in the clinical setting. Beyond the key findings from SEQUOIA-HCM, we've got a strong scientific communications strategy lined up for the next 12 months, involving papers and Congress sessions that will dig deeper into how aficamten impacts additional exercise capacity measures, cardiac remodeling based on the CMR sub-study, echo assessments of systolic and diastolic function plus cardiac structure, symptoms and quality of life, and cardiac biomarkers. We're eager to share these findings with you during 2024, beginning in Q2. I want to recognize the incredible work from our steering committee and internal groups in backing and carrying out this bold publications and presentations initiative. Turning now to FOREST-HCM, our open-label extension trial for aficamten, we can share that more than 90% of eligible patients from REDWOOD-HCM and SEQUOIA-HCM have joined FOREST-HCM, which amounts to close to 300 patients who will help advance our knowledge of aficamten's long-term treatment effects. Just to clarify, this excludes patients in the China cohort of SEQUIOA-HCM; those individuals will ultimately enter a China-specific open-label extension trial; in April, at the American College of Cardiology Annual Scientific Sessions, we'll share the efficacy and safety profile of aficamten in the initial group of symptomatic obstructive HCM patients who have reached 1 year of follow-up in FOREST-HCM. Last month, we presented data at CMR 2024 from the cardiac magnetic resonance, or CMR, sub-study of FOREST-HCM. Those results indicated that 48 weeks of aficamten treatment led to cardiac structural remodeling, better cardiac function, and stabilization of myocardial fibrosis, showing that aficamten may have potential disease-modifying effects and the capacity to enhance heart architecture in obstructive HCM patients. Although this analysis is limited, with only 16 patients eligible when the data cut occurred, we intend to build on these findings going forward as additional patients hit the 1-year point and beyond. On the regulatory side, in February we conducted 2 meetings with FDA prior to our anticipated NDA submission in the third quarter of this year—an initial meeting to go over SEQUOIA-HCM results, and a second pre-NDA meeting, which gave us a chance to align on the NDA's content and format. We're happy with the FDA's feedback, which supports the adequacy of our proposed NDA submission package and their openness to a rolling submission approach. We think the positive SEQUOIA-HCM readout, together with aficamten's favorable pharmacologic and PDI profile, continue to back the chance for differentiated labeling and risk mitigation. We're looking forward to giving future updates on our FDA interactions this year. When it comes to regulatory planning and interactions in Europe, we're likewise getting ready to submit our marketing application in the fourth quarter of this year and intend to meet with EMA in Q2 to guide our preparations. In the same way, we're working with our partner, Ji Xing, in China to jointly support Ji Xing's plan to submit an NDA. On the whole, because we planned proactively during 2023, we've been able to take advantage of the favorable findings from SEQUOIA-HCM and move quickly toward regulatory filings around the world, and also to evaluate accelerated routes in line with our most ambitious planning scenarios. Beyond that, from the medical affairs side, over the quarter our therapeutic medical science liaisons kept building profiles of HCM treatment programs, and our managed healthcare and medical science liaisons started putting together our payor clinical value proposition. Our backing of medical education efforts at medical conferences also carried on. As Robert mentioned, the specialty cardiology company we're constructing draws its strength from the force of our research engine and development pipeline, with aficamten, should it be approved, out in front. The topline results from SEQUOIA-HCM have gotten a warm reception from the HCM community of physicians and patient advocates, who expect these findings could represent a meaningful step forward in care. We appreciate their backing, and we're eager to keep working with them as we strive to position aficamten as a possible next-in-class treatment choice for patients with HCM; now I'll pass things to Stuart, who will go into more detail about further clinical trials progress we're making with aficamten and give an update on our earlier-stage clinical development pipeline.
Stuart Kupfer
executiveThank you, Fady. Along with reporting favorable findings from SEQUOIA-HCM, we kept enrolling patients during Q4 and are gaining traction across our 2 ongoing Phase III studies of aficamten, MAPLE-HCM and ACACIA-HCM. It's encouraging that screening and enrollment are picking up speed, spurred on by the release of SEQUOIA-HCM results. MAPLE-HCM is assessing whether aficamten might be superior as a monotherapy versus metoprolol as a monotherapy for patients who have obstructive HCM; at this point, virtually every site in the U.S. is up and running, and we've also brought sites online in the U.K., France, Italy, the Netherlands and Israel. We anticipate finishing enrollment for MAPLE-HCM during Q3 of this year, which should make MAPLE-HCM results ready in 2025, at the same time we're hoping to be launching aficamten commercially. Should MAPLE-HCM produce a positive readout, we think that would help establish aficamten's positioning as a first-line therapy for obstructive HCM patients. Our aim in developing aficamten is to seize this next-in-class opportunity, and MAPLE-HCM plays a major role in that approach. Turning to ACACIA-HCM, our pivotal Phase III study of aficamten in symptomatic nonobstructive HCM patients, the focus right now is study start-up, though we already hold the IRB approvals we need in the U.S.; and in the EU, our clinical trial application is moving through the new harmonized procedure. Investigator meetings for North America, South America, and Europe are slated for Q2, and we look forward to keeping enrollment going in this study throughout 2024, aiming to finish enrollment in 2025. ACACIA-HCM is a significant opportunity for aficamten and puts the central therapeutic hypothesis to the test as we broaden the evidence behind cardiac myosin inhibition for a growing patient population that current treatments don't adequately serve. Thanks to the SEQUOIA-HCM and REDWOOD-HCM results, we believe we have added confidence about what ACACIA-HCM may deliver, and clinical investigators share that optimism. Either study could widen how aficamten is used among HCM patients and shape treatment guidelines. Simultaneously, we're happy with how our aficamten trials are progressing. During the last quarter, we also moved our earlier stage pipeline forward, particularly CK-586, our cardiac myosin inhibitor being developed as a possible treatment for a subgroup of heart failure with preserved ejection fraction, or HFpEF, patients. Once we finished analyzing the single ascending dose data, we moved on to the multiple ascending dose part of the study. We anticipate wrapping up the Phase I study this quarter and then sharing data in Q2 of this year, with plans to kick off a Phase II trial in the year's second half. We believe the positive Phase II data we produced for aficamten in nonobstructive HCM patients bolsters the development of CK-586 for the HFpEF population. That condition shares many parallels with nonobstructive HCM. Right now in the U.S., roughly 3.6 million individuals are living with HFpEF, and that figure is projected to reach 4.8 million by 2033. Somewhere between 30% and 40% of those patients have traits that could mean their condition responds to cardiac myosin inhibition. Despite SGLT2 inhibitors being the first evidence-based treatments to show any benefit for people with HFpEF, a substantial residual risk of cardiovascular events remains, and there is an obvious demand for further effective options. Also, over the last quarter, regarding CK-136, our cardiac troponin activator, we kept analyzing the single and multiple ascending dose cohorts in the Phase I trial involving healthy participants, and we anticipate finishing that study in the second quarter of this year. During 2024, we intend to provide additional updates from our early-stage pipeline and our research. As additional programs advance out of our labs and into the clinic, we will describe how, over recent years, we have broadened our concentration in muscle biology past muscle contractility to encompass other programs now entering development, which represent possible breakthroughs in muscle metabolism and energetics. Although aficamten is the most significant near-term value driver for our company, our early-stage pipeline and emerging programs from continuing research show productivity in line with our Vision 2025. The ultimate aim is to solidify our leadership in muscle biology alongside exciting advances and treatments for cardiometabolic syndromes. We are eager to share further progress shortly; with that, I will hand the call to Andrew.
Andrew Callos
executiveThank you, Stuart. In the quarter, before we shared the SEQUOIA-HCM findings, we kept up our commercial readiness work for aficamten. All through 2023, our emphasis was on learning — the opening stage of how we approach going to market. We sponsored several market research efforts, gathering perspectives from close to 850 healthcare professionals as well as over 160 patients living with obstructive HCM, and those studies showed that the HCM patient journey is often complicated and difficult. On top of that, HCM may also harm patients' mental health overall, their social engagement and other parts of daily life; we additionally evaluated various product profiles and market research before we obtained the SEQUOIA-HCM results. The attributes we tested that came nearest to the real SEQUOIA-HCM findings showed that healthcare professionals would view the SEQUOIA-HCM results positively and that this would fuel adoption of aficamten, should it be approved, among a wide spectrum of obstructive HCM patients. What we've learned shapes the strategic choices we are making regarding the target product profile, positioning potential customer profiles at our patient services hub. Access especially is a central priority for us. Consistent with our company values of keeping patients at the forefront of everything we do, we are creating a thorough patient support program to help and assist patients as they move onto treatment with aficamten, including patient education materials plus reimbursement support and affordability programs for patients who qualify. During Q4 of 2023, we had initial discussions with specialty pharmacies and patient service hub providers to help us build a differentiated patient services hub. Since we now have SEQUOIA-HCM results this year, we are moving into the second and third phases of our go-to-market strategy — design and build; in 2024, we intend to build our patient support services and access strategy, covering distribution model, contracting approach and pricing. Our experienced account manager team is fully staffed and met with every major payor during 2023 to introduce Cytokinetics. This field-based payor account team will keep engaging further in 2024 to share the SEQUOIA-HCM results and make sure payors grasp the clinical meaningfulness of those results. In 2024, we also intend to lock in our product positioning and kick off our market development and education campaign as we create our branded marketing campaign to back our potential 2025 promotional launch. As we said before, we started developing our commercial capabilities in the United States ahead of the possible FDA approval and launch of omecamtiv mecarbil. Once we received the CRO from the FDA, we kept the infrastructure already built and further honed the team and activities to get ready for what will now be our first commercial launch with aficamten. As of today, we have brought on board most of the U.S.-based headquarter personnel we anticipate needing, such as marketing, field sales leadership, and people heading insight generation, market analysis, commercial strategy, systems, and operations; we expect to grow the team in 2025 with ATP customer-facing positions gated suitably alongside the regulatory process for aficamten. Over in Europe, we filled several important leadership roles during the past year, among them our Head of Europe and our Head of Market Access. For 2024, our intention is to grow the EU team only slightly, all while keeping tight control over expenses and tying spending to regulatory submissions and the feedback we receive from health technology assessments, or HTAs. It's heartening that HTAs in Germany as well as France have given favorable benefit assessments for cardiac myosin inhibitors as a novel therapeutic choice for obstructive HCM patients, and in our view that signals good things for aficamten's future reimbursement, should it gain approval, throughout the major European markets. On the whole, I'm extremely happy with the foundational commercial readiness efforts we finished before we shared our SEQUOIA-HCM results last year, which positions us to move flexibly into the following stage of our planning during 2024 and can let us take advantage of what we expect will be differentiated positioning for aficamten in treating obstructive HCM patients. With that said, I'll hand the call to Robert Wong.
Robert Wong
executiveThanks, Andrew. We closed out Q4 with $655.4 million in cash and investments, and that figure includes $162.9 million brought in during the quarter through our at-the-market equity vehicle. After the quarter ended, we brought in roughly $83 million net through yesterday using that same ATM equity vehicle, and that amount isn't part of our year-end balance. R&D expenses for the fourth quarter of 2023 rose to $85 million, up from $75 million in the fourth quarter of 2022, mainly because of what we spent on our cardiac myosin inhibitor programs. G&A expenses for Q4 2023 came to $44.1 million, lower than the $54 million recorded in Q4 2022, driven largely by reduced outside spending on commercial activities, partly offset by increased personnel-related costs, which include stock-based compensation. On the whole, net cash burn for 2023 totaled $414 million, compared with our original 2023 guidance range of $420 million to $450 million; we feel we demonstrated good stewardship of shareholder capital by cutting spending before the SEQUOIA-HCM results came in at the end of the year, leaving us in a stronger financial position entering 2024. I'll now turn things over to Robert Blum, who will walk through our financial outlook, 2024 guidance, and corporate development strategies.
Robert Blum
executiveThanks, Robert. We put out our financial guidance for 2024 earlier today. Revenue is expected by the company to land somewhere between $3 million and $5 million. Operating expenses should fall in a range of $420 million to $450 million, while net cash utilization is projected at roughly $390 million to $420 million. When it comes to capital allocation, we're prioritizing patient benefit and shareholder value enrichment, and that's built on a disciplined spending approach that weighs pushing our commercial strategy forward against putting money into our pipeline. Above all else, our top priority is moving regulatory submissions for aficamten in obstructive HCM ahead and making sure we're commercially ready in key markets such as the U.S. and Europe. Second, by carrying on MAPLE-HCM and ACACIA-HCM, we intend to get the most therapeutic value possible out of aficamten. And third, we're staying committed to expanding our pipeline, which includes CK-586, and strengthening our R&D platforms so future innovation can be sustained. When you factor in roughly $83 million in net proceeds raised lately through our ATM plus the cash we can access under our loan agreement with Royalty Pharma, the $655 million in cash we held at the close of last year works out to about 2 years of forward cash runway, based on our guidance and the operating expenses and net cash utilization we project for 2024. Now that we have positive SEQUOIA-HCM results in hand, we've been examining what capital requirements will look like along the path toward possible approvals and the worldwide commercial launch of aficamten, as well as keeping R&D going and growing it all the way to profitability. So we're still pursuing a multipronged strategy for accessing capital, one that lets us pull a number of different levers as time goes on. True to our history, our plan is to monetize the progress we make in R&D and protect shareholder value through partnering, structural finance engineering, and other nondilutive routes. Business development continues to be where our priority lies. You already know that securing a Japanese partnership for aficamten has been one of our priorities. Conversations are underway with multiple companies, and I'm pleased with how that partnering effort is progressing. Beyond that, we're exploring a collaboration for CK-586 as a possible therapy for HFpEF, while retaining important Cytokinetics rights in both co-development and co-commercialization. We think the fact that we've led the field in cardiac myosin modulation for severe cardiovascular disease for so long means we can go into partnering talks from a position of strength — in a way that serves shareholders and still keeps a lot of shareholder value in the key markets that matter for aficamten. On top of that, we could look at restructuring our debt and other new ideas to keep building on the momentum from SEQUOIA-HCM, using structured finance transactions that in our view would add to shareholder value and, just as important, wouldn't subtract from it. One thing I want to flag: because of the deal we did with Royalty Pharma, we can still draw 2 more loan tranches under our development funding agreement. The first tranche, worth $75 million, was unlocked when we shared positive SEQUOIA-HCM results, and we can still draw down for 1 year after we received those results, which happened in late December. A second $100 million tranche would be accessible for us to tap if we decide to do so, provided certain requirements are met — the most significant being that an NDA for aficamten gets accepted in the United States. Now that our company carries a valuation in the range of $8 billion to $10 billion, we have a plan that is ambitious but also practical and realistic for boosting shareholder value across the coming 3 to 5 years, taking it to somewhere above $15 billion to $20 billion. So how do we reach that? By unlocking what our pipeline holds and getting the most out of our opportunities. It begins with aficamten in North America and Europe, drawing on what SEQUOIA-HCM showed. After that, we aim to build further value as MAPLE-HCM and ACACIA-HCM produce results, which now carry a greater likelihood of technical success. Following that, we anticipate CK-586 moving through proof of concept in HFpEF, with extra upside provided by our earlier stage pipeline. I'd also like to briefly speak to the recent M&A speculation surrounding Cytokinetics. Ever since we shared the positive SEQUOIA-HCM results, there have been rumors that Cytokinetics is a target for acquisition. We won't and can't address particular rumors, but please let me be clear on one point: no sale process was started by us, nor is one currently underway. That said, as responsible fiduciaries for our shareholders, I can assure you we carefully assess any options put in front of us; and as I said a moment ago, we keep moving business development discussions forward. We're encouraged by where those talks are heading, and our dedication to creating a durable specialty cardiology business stays firm — and that starts with fulfilling our goal of getting novel treatments to patients. We take our obligation to shareholders seriously, working to secure the greatest possible value and focusing on the things we can influence; in our view, the strongest path to that outcome is pushing our pioneering science forward, keeping operations efficient, and handling and allocating capital with care and good judgment so shareholder value is maximized. As we enter 2024, we hold a favorable position. We've entered a new phase in the Cytokinetics narrative, and the efforts currently underway are going to lay the groundwork for what could be our first approvals from regulators, something we're hoping will come about in the coming 18 months. In the latter half of this year, we anticipate filing for regulatory clearance for aficamten in the U.S. as well as in Europe. Fady has walked you through an NDA in Q3 with FDA and an MAA in Q4 with EMA. We're looking to give you greater specificity around timing when we hold our Q1 earnings call, especially when it comes to positioning and other elements that make up the substance of those submissions. We also have big aspirations that go past obstructive HCM and past aficamten, too—such as growing our development pipeline through additional compounds that come out of our research, which reaches past muscle contractility into muscle energetics, growth, and metabolism. Each of our muscle biology programs came about with the aim of potentially helping seriously ill, underserved patients who are in need of fresh treatment choices. And our vision of building a specialty cardiology company is now becoming real, and we're in a strong position to do well. With that said, I want to move on to the milestones we expect in 2024. When it comes to aficamten, we anticipate presenting the primary results from SEQUIOA-HCM at a medical conference during Q2 2024; we anticipate filing an NDA with the FDA in Q3 2024, along with an MAA to the EMA in Q4 2024. We anticipate finishing enrollment for MAPLE-HCM in Q3 2024. For ACACIA-HCM, we anticipate finishing enrollment in 2025, while continuing that enrollment through 2024, and we anticipate continuing to move forward with go-to-market strategies for aficamten; regarding omecamtiv mecarbil, we anticipate that the CHMP will issue an opinion on the MAA in Q2 2024. Regarding CK-586, we're looking to present results from the Phase I trial during Q2 2024. Then with CK-136, our goal is to wrap up a Phase I study in this year's second quarter. With that covered, operator, let's go ahead and take questions from callers now.
Mayank Mamtani
analystI also want to wish Chang well. On the pre-NDA meeting that took place, I'm just wondering what portion of the FOREST-HCM data would be included in that submission? My understanding is that by the ESC Heart Failure Congress, roughly 150 patients would likely have completed the titration phase. So I'm curious whether — how much of that will matter for the pre-NDA meeting and ultimately end up in the NDA submission?
Robert Blum
executiveI'll hand that call — that question, rather, to Fady.
Fady Malik
executiveProviding a precise patient count isn't something I'm able to do. That said, beyond how many patients already had longer-term follow-up within FOREST when the NDA went in, there will also be a chance for us to file an update once we reach the Day 120 mark. At that Day 120 safety update, the dataset can be broadened. As a result, we're quite confident that the total number of patients reaching as much as a year of follow-up will be more than sufficient for their review.
Mayank Mamtani
analystGot it. And one more thing on this, quickly — regarding ACACIA-HCM, I appreciate that you tightened up the timing there. I was simply wondering, taking into account all the information we have about dosing, safety, and cardiac remodeling data, how confident you are about that, and what you might be able to report; also keeping in mind that a threshold might be established from the ODYSSEY-HCM study coming next — early next year.
Fady Malik
executiveWell, I'd say given what we observed in Phase II, plus how predictable the dosing is and the safety profile aficamten showed in SEQUOIA, our confidence is very high regarding the outcomes and possible outcomes in ACACIA. I think each of those looks favorable for the likelihood that trial will read out positively, and we'll keep running it in a manner that helps us arrive at the best answer.
Robert Blum
executiveAppreciate you asking that. And if I could just note, let's keep it to a single question for each analyst, if you don't mind. Let's take the following question now.
Salim Syed
analystRobert, I'd like to zero in on — and maybe Fady should weigh in too — the rolling submission. What precisely is being filed first? Also, unless I'm wrong, this is the debut of that phrase from you folks for aficamten. So which components go in initially, and which parts do you intend to hand over afterward? I'm also wondering whether that rolling submission somehow includes the possibility of filing the MAPLE-HCM data, since you'll have it in hand prior to an approval decision.
Robert Blum
executiveYes. I'll take that one. You're correct that this terminology is new from us, and it emerged from our recent conversations with FDA. Their apparent forward lean and readiness to look at these data earlier has us quite encouraged. We're exploring ways to speed up submission. Along those lines, they were receptive to our proposal to proceed on a rolling basis. Most of the modules will go in ahead of what amounts to the longest lead item, so to speak — arriving afterward will be a portion of the CMC data still being completed, given that specific timepoints must be gathered before those submissions can be wrapped up. All of this, we believe, points to a forward-looking emphasis tied to a submission capable of starting earlier. Bear in mind that the actual filing itself remains unchanged; it hinges in the end on the final modules at the moment they're turned in, yet this definitely permits the review to get underway.
Fady Malik
executiveWhen it comes to MAPLE, no, our expectation isn't that this submission will include those data. We won't see MAPLE read out until next year.
Fatima Amanat
analystThis is Fatima, and I'm asking for Ashwani Verma at UBS. I've got one quick, general question. When it comes to cardiology overall, at a high level, is it typical for a portfolio to be contracted? For instance, could that kind of approach mean that businesses offering a wide range of products might, in the longer term, gain an advantage from scale?
Robert Blum
executiveThat question isn't clear to me. Could you say it again, please?
Fatima Amanat
analystAlright, so I'm simply attempting to get a handle on this — within cardiology, is there a shift toward contracting at the portfolio level? In other words, do you figure that businesses holding a wide and varied range of cardiology offerings gain some kind of bigger advantage over those that zero in on just one asset?
Robert Blum
executiveGot it. What you're asking is whether we could end up at a disadvantage since our launch will involve just one product, while payors — as I take it — may be dealing with several, perhaps negotiating contracts covering several products. Did I get that right?
Fatima Amanat
analystYes.
Stuart Kupfer
executiveWhen you look at it through a payor lens, no, I don't think we're disadvantaged. This category isn't something payors are managing. It's a rare disease. In the U.S., there are more than 120 payors. Every payor sees just a very small number of patients. The budget impact isn't large. The unmet need is high. One product is on the market, and a second product. From a cardiology standpoint, these typically aren't categories that payors manage. A subset of cardiologists is where our focus will be — those who diagnose and treat HSM within the broader field of cardiology and who are highly motivated to treat this disease. They'll concentrate more on the products and on the patients with the disease. Absolutely, I believe we'll compete well, and no disadvantage will apply.
Carter Gould
analystHey, this is Carter. I appreciate you fielding my question, Robert. This might be directed at both Robert and Fady — regarding the REMS commentary, the reference to SEQUOIA, and the PK and DDI profile, all of which I think we've been aware of for some time now — but could you say whether the FDA interactions have in any way changed or reinforced your confidence in that differentiated label for REMS? Thank you.
Robert Blum
executiveSure. I'll keep my remarks very short; it's too early to say since those discussions are ongoing, but we continue to hold the view that when it comes to positioning, labeling, a reduced REMS, and other matters that bear on safety and risk mitigation, we will be able to have a highly productive and fruitful dialogue with the FDA.
Paul Choi
analystRegarding the meeting you had recently with the FDA, could you just verify whether the agency laid out any preclinical or clinical testing stipulations? And if there are any, what portion of that has to be aligned with EMA requirements before a possible MAA submission, on top of the NDA?
Robert Blum
executiveCertainly. Our view is that no additional studies of that kind are needed. I think that answers what you asked. Thank you.
Adhiraj Chauhan
analystThis is Adhi calling in place of Tess. There's one thing we wanted to ask: as of right now, is there any information out of SEQUOIA that hasn't reached you yet?
Robert Blum
executiveI'll hand that question to Fady.
Fady Malik
executiveThe complete data set has now come into our hands. I can't claim that each and every analysis one might conceive of is finished. Honestly, that work could continue for years, since fresh analyses keep occurring to us. Still, every one of the prespecified analyses — the clinical study report, for instance — is done and has gone through thorough review.
Robert Blum
executiveThis will likewise be shown to you in all its detail during the second quarter. Our expectation is several presentations as well as several publications.
Yasmeen Rahimi
analystSo I believe it's 2 months now since we got the topline data. Have you managed to finish all the ramp preparation — bringing on the consultants, going through the data in an integrated way, putting together a package, and sort of setting out the proposal? Could you give us some sense of which of those activities are done? What still needs doing? And how much of the proposal would you say is in the final stages?
Robert Blum
executiveThanks, Yasmeen. I'll handle that one. What you're describing is exactly what we're working on right now. My sense is that this isn't the sort of matter we'll opt to discuss in detail in a public setting. Clearly, it plays into how we compete. To build on what Carter asked, I genuinely think we may be in a position to look at how we could be differentiated and advantaged in ways that might help aficamten reach more physicians and more patients. As for how that REMS might be positioned, where it sits, and which elements it would include — my view is that this will ultimately be negotiated during the review period of an NDA, once it's on file. So I don't anticipate giving play-by-play visibility on that until we feel there's certainty about what it will look like.
Jose Lora
analystThis is Jose, sitting in for Jason. You brought up that FOREST-HCM's data shows favorable structural remodeling. Could you talk about what long-term functional gains that kind of remodeling might bring for HCM patients? And just one quick follow-up regarding aficamten — do your conversations with payors reveal anything about how risk pricing might compare with the standard of care?
Robert Blum
executiveFor that first question, I'll turn it over to Fady or Stuart.
Stuart Kupfer
executiveAbsolutely, that's an important thing for us to look into, no doubt over the long haul. Our hypothesis is that inhibiting cardiac myosin is going to produce, in the long run, remodeling that's quite favorable and, with luck, normalization. As for the heart's structure and its function, we expect that to bring about — to deliver — benefit across a patient's lifetime when it comes to how symptoms and function improve. On top of that, we might also speculate about a lower likelihood of cardiovascular events.
Fady Malik
executiveLet me just mention that what we shared back in January is only an initial glimpse from the CMR cohort, which I believe represents the biggest group of patients who will be getting serial CMRs at 1 — either yearly or on an every-other-year basis; therefore that figure, that duration, those findings are going to evolve as time passes and, in my view, will provide us with a really solid understanding of the way cardiac structure transforms over the years.
Stuart Kupfer
executiveOn the pricing side, once the SEQUOIA-HCM results come out, we'll share those findings with payors. Right now, there's obviously one product available that carries a list price. Our price will land somewhere around that list price. If we end up a bit higher, a bit lower, or right at it, we haven't locked in our final pricing position yet, but we'll settle that as launch approaches next year.
Robert Blum
executiveAnd at this stage, those aren't the sort of matters a person brings up.
Joe Pantginis
analystMy question probably fits Andrew best, or at least it's most appropriate for him. From where you sit internally, I realize you'd rather not discuss how the competition looks or what's running through your minds; still, I'm curious whether your marketing research, your conversations with physicians, your polling and so forth, whether the profile data that came out of SEQUOIA has generated anything you're able to share about how willing doctors are to move patients off Camzyos at an early stage, or whether they feel they need additional real-world evidence before they can become educated regarding the drug aficamten?
Andrew Callos
executiveThat hasn't been our area of emphasis. Our entire emphasis is on ensuring that patients taking beta blockers, calcium channel blockers, those not receiving standard of care, those not receiving disease-modifying therapy, are activated towards the CMI. Get those physicians educated on, hopefully, the label and the REMS program tied to aficamten, which will soon be approved. Our emphasis will be on activating patients and getting them onto therapy. Patients who already receive an existing therapy won't be our emphasis; whether they decide to take that path is genuinely a matter for the physician and patient to discuss.
Robert Blum
executiveWhen you have something with the potential to be best-in-class, which is how we see aficamten, we have a responsibility to consider how it could grow the category and ultimately help more patients — and that is exactly where we are directing our attention.
Andrew Callos
executiveWe also believe the eligible patient population is quite large — more than 100,000, in fact. Our working assumption is that by the time we launch, most of them will not yet have received CMI therapy and will remain candidates for it.
Hyunji Sun
analystKatherine here, filling in for Jeff, and we've just got a quick question. I'm wondering about the talks or exchanges you've had with providers. Has any excitement come through regarding a possible REMS program that's less restrictive? Or have they given any sign that in their view the data could back that up?
Stuart Kupfer
executiveSo, we have definitely had discussions with providers, and because of the safety profile we presented to them in the SEQUOIA data, they're hopeful. But clearly, they aren't the ones contributing to how the FDA assesses that matter. And what we put forward will be based on what we've found and the data we've gathered so far, so just keep watching.
Roanna Ruiz
analystCould you talk a bit about what the opportunity looks like in Europe for aficamten? Also, are there similarities or differences we ought to keep in mind relative to the U.S., and what might the timeline be for building out a bigger commercial footprint in Europe?
Fady Malik
executiveOn the European side, you've already heard the filing dates. When it comes to prevalence — the count of patients — it's a bit greater, simply because the total population is a bit greater. Pricing sits below the U.S., likely somewhere between 15% and 25%, varying by country. As far as opportunity goes, after approval happens, Germany is where we'll launch. That makes launch possible right at approval. In other markets, you have to file for reimbursement and negotiate pricing; so broadly speaking, for market opportunity outside Germany, Europe will likely run roughly 1 year behind on launch.
Billal Jahangiri
analystBillal here, filling in for Kripa. In your analysis of the data, is there any way to forecast which patients receiving aficamten would be more prone to experiencing LVEF declines? Also, might that get built into your REMS program? And over time, are you observing LVEF stabilization?
Stuart Kupfer
executiveRegarding your second question, yes is the answer, and those data have been reviewed by us, and we have in fact presented them. In FOREST, you'll see some of this, where EF over time is shown going out as far as a year. It appears quite stable. As for susceptibility factors, I believe you can, in a sense, obviously forecast who could be susceptible. Those are patients who, once titration is complete, have EFs of 50%, 55%. They might carry greater risk since they sit nearer to the cutoff; that's fairly obvious. And I think whenever you examine any monitoring strategy used in medicine, typically you focus on patients nearer to particular thresholds. You watch them more closely than other patients who are farther away from it. That will definitely be incorporated into our thinking.
Cameron Bozdog
analystThis is Cameron Bozdog, filling in for Jason. Congratulations on the quarter, and we appreciate you taking our question. When it comes to your commercial outlook, how significant is usage in the community setting, particularly regarding the frontline opportunity? What do you believe is required so that community prescribers become more at ease giving afi, especially considering it will probably carry a REM? After that, how much time do you anticipate this transition will require?
Stuart Kupfer
executiveBy community, I take it you're still referring to cardiology — community cardiology?
Cameron Bozdog
analystYes, that's right.
Stuart Kupfer
executiveCurrently, a bit more than 1,000 people prescribe CMI. If you examine claims data, roughly 10,000 cardiologists are the ones driving diagnosis. A smaller portion of general cardiology accounts for about 80% of diagnosis. Usually, specialty product launches move from a core group to the outside. That expansion happens gradually. I believe the REMS likely makes it somewhat slower. As more education takes place, and as patients arrive in general cardiology already taking a CMI, things will speed up, particularly during the maintenance phase. It's difficult to pinpoint when that moment will arrive, but it will definitely happen gradually given how many patients require treatment.
Serge Belanger
analystMy question is about the SEQUOIA presentations coming up. Could you explain why you decided to present at the heart failure meeting instead of next month's ACC meeting? And what additional data and analyses might we expect from those results?
Robert Blum
executiveAbsolutely, I'll handle that. When we top lined SEQUOIA-HCM's results, we recognized a risk: we might clash with an ACC policy about accepting abstracts when the material is already otherwise in the public domain at the time they review that abstract. We also recognized a material obligation to shareholders to disclose what we did choose to disclose. So our SEQUOIA abstract wasn't accepted by ACC — our assumption is because it had already been disclosed in considerable detail through a press release. As a result, the following meeting is the HFA meeting, which takes place a month afterward in May in Lisbon. That's where we hope these data will be presented. Whether that happens hasn't been settled yet. At the same time, we anticipate it will be presented and possibly published concurrently in and around the second quarter. I hope that addresses your question, but we expect that not only will these primary efficacy and safety results be presented and published, but even more so alongside other secondary analyses and certain post-hoc analyses as well; we think we have an aggressive communications plan for presentations and publications, and you'll see multiple presentations and publications during that period.
Charles Duncan
analystRobert and everyone, congratulations on the momentum. On that final point, ACC strikes me as somewhat lacking in foresight. There are a pair of brief questions I'd like to pose that perhaps you won't be in a position to address. The first is fairly straightforward: are you expecting an AdCom to be convened? The second is trickier to field, namely, which pulls you more strongly — pharmacoeconomic modeling that backs, let's say, premium pricing? Or a tie to the standard of care? I realize pricing isn't really something you're discussing, but I'm just after your viewpoint.
Robert Blum
executiveRegarding an AdCom, that's simply unknowable on our end. What we can say is that no AdCom took place for mavacamten. That fact doesn't automatically mean no AdCom would occur for us; should one be scheduled, we'll be ready, yet at this point nobody can have that knowledge, and definitely not before a submission gets accepted for filing. As for what pulls us in connection with pricing, I won't address pricing itself, though I will say we're strongly drawn to the HEOR datasets currently being readied and examined, and to how they tie into the value surrounding aficamten. That, together with various other considerations, in the end feeds into the factors that will determine pricing. That's honestly the most I can offer you today.
Robert Blum
executiveThanks, Operator. There was a great deal we got into today, through both our prepared remarks and the Q&A as well, so I'll keep this short. I'll just note that, with the SEQUOIA results, we genuinely feel we've flipped a significant page and begun the next chapter for Cytokinetics, and at the same time we'll stay watchful when it comes to execution and to treating shareholders rightly. The science leaves us humbled, yet we're also pressing ahead toward what aficamten makes possible — not only where OHCM is concerned, but also, we believe, in unlocking further value creation. We look forward to keeping shareholders informed about that progress. And on that note, Operator, please go ahead and close out the call.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.